Siena, S., Elez, E., Peeters, M., André, T., Van den Eynde, M., Ng, K., … Van Cutsem, E. (2021). PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress). In Annals of Oncology (Vol. 32, pp. S199–S199). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.05.019

Siena, S., E. Elez, M. Peeters, T. André, M. Van den Eynde, K. Ng, A. Cercek, et al. “PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).” In Annals of Oncology, 32:S199–S199. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.05.019.

Siena S, Elez E, Peeters M, André T, Van den Eynde M, Ng K, et al. PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress). In: Annals of Oncology. Elsevier BV; 2021. p. S199–S199.

Siena, S., et al. “PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S199–S199. Crossref, doi:10.1016/j.annonc.2021.05.019.

Siena S, Elez E, Peeters M, André T, Van den Eynde M, Ng K, Cercek A, Fountzilas C, Sanchez F, Hubbard J, Wu C, Tabernero J, Kardosh A, Saeed A, Strickler J, Bekaii-Saab T, Stecher M, Palanca-Wessels M, Van Cutsem E. PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress). Annals of Oncology. Elsevier BV; 2021. p. S199–S199.